Close Menu
Home › Multi-Gene Hereditary Breast Cancer Tests Double Detection Rate; Don't Spur Breast Removal

Multi-Gene Hereditary Breast Cancer Tests Double Detection Rate; Don't Spur Breast Removal

May 10, 2018

NEW YORK (GenomeWeb) – Multi-gene germline testing of breast cancer patients doubles the detection of disease-causing variants that could result in a change of care, compared to BRCA1- and BRCA2-only testing, though it does not increase prophylactic breast removal, according to a large new retrospective population-based study.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Jul
23
Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

What's Popular?

In Cancer

  1. Next-Generation Sequencing of Pediatric Cancer Patients Could Transform Treatment Paradigms

    Premium

  2. Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer

  3. Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program

  4. Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug

  5. AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.